Advertisement

Hereditary Xanthine Oxidase Deficiency Consisting of at least Two Subgroups

  • Kazuya Higashino
  • Tetsuya Yamamoto
  • Toshikazu Hada
  • Norio Kono
  • Masanori Kawachi
  • Masahisa Nanahoshi
  • Sumio Takahashi
  • Michio Suda
  • Michiko Naka
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 253A)

Abstract

Previous studies1–6 indicated that though pyrazinamide was metabolized into 5-hydroxypyrazinamide, its deamidated form, pyrazinoic acid, could not be metabolized into 5-hydroxypyrazinoic acid in a xanthinuric patient and normal subjects pretreated with allopurinol. On the other hand, several studies on the metabolism of allopurinol in xanthinuric patients demonstrated that allopurinol was not converted to oxypurinol 7–10 and yet others demonstrated that allopurinol was converted to oxypurinol in xanthinuric patients 11–13. We were interested in what enzyme other than xanthine oxidase related to human metabolism of pyrazinamide and allopurinol and what caused the discrepancy between these different results in the metabolism of allopurinol in xanthinuric patients. Therefore, we conducted a study on the metabolism of pyrazinamide and allopurinol in two patients from different families.

Keywords

Uric Acid Urinary Excretion Xanthine Oxidase Xanthine Oxidase Activity Xanthine Dehydrogenase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    I. M. Weiner, and J. P. Tinker, Pharmacology of pyrazinamide: Metabolic and renal function studies related to the mechanism of drug-induced urate retention, J. Pharmac. Exp. 180: 411 (1972)Google Scholar
  2. 2.
    D. Pitre, R. M. Facino, M. Carini, and A. Carlo, In vitro biotransformation of pyrazinamide by rat liver: Identification of a new metabolite, Pharmac. Res. Commun. 13: 351 (1981)CrossRefGoogle Scholar
  3. 3.
    C. Auscher, C. Pasquir, P. Pehuet, and F. Delbarre, Study of urinary pyrazinamide metabolites and their action on the renal excretion of xanthine and hypoxanthine in a xanthinuric patient, Biomedicine 28: 129 (1978)PubMedGoogle Scholar
  4. 4.
    T. Yamamoto, Y. Moriwaki, S. Takahashi, T. Hada, and K. Higashino, 5-Hydroxypyrazinamide, a human metabolite of pyrazinamide, Biochem. Pharmac. 36: 2415 (1987)CrossRefGoogle Scholar
  5. 5.
    T. Yamamoto, Y. Moriwaki, S. Takahashi, T. Hada, and K. Higashino, In vitro conversion of pyrazinamide into 5-hydroxypyrazinamide and that of pyrazinoic acid into 5-hydroxypyrazinoic acid by xanthine oxidase from human liver, Biochem. Pharmac. 36: 3317 (1987)CrossRefGoogle Scholar
  6. 6.
    T. Yamamoto, Y. Moriwaki, S. Takahashi, T. Hada, and K. Higashino, Study of the metabolism of pyrazinamide using a high-performance liquid Chromatographic analysis of urine samples, Analyt. Biochem. 160: 346 (1987)PubMedCrossRefGoogle Scholar
  7. 7.
    K. Engelman, R. W. E. Watts, J. R. Klingenberg, A. Sjoerderma, and J. E. Seegmiller, Clinical physiological and biochemical studies of a patient with xanthinuria and pheochromocytoma, Am. J. Med. 37: 839 (1964)PubMedCrossRefGoogle Scholar
  8. 8.
    G. B. Elion, A. Kovensky, G. H. Hitchings, E. Metz, and R. W. Rundels, Metabolic studies of allopurinol, an inhibitor of xanthine oxidase, Biochem. Pharmacol. 15: 863 (1966)PubMedCrossRefGoogle Scholar
  9. 9.
    H. A. Simmonds, B. Levin, and J. S. Cameron, Variations in allopurinol metabolism by xanthinuric subjects, Clin. Sci. Mol. Med. 47: 173 (1974)PubMedGoogle Scholar
  10. 10.
    E. W. Holmes, D. H. Mason, L. I. Goldstein, R. E. Blount, and W. N. Kelley, Xanthine oxidase deficiency: studies of a previously unre-ported case, Clin. Chem. 20: 1076 (1974)PubMedGoogle Scholar
  11. 11.
    H. A. Simmonds, Urinary excretion of purines, pyrimidines and pyrazolo-pyrimidines in patients treated with allopurinol or oxypurinol, Clin. Chim. Acta 23: 353 (1969)PubMedCrossRefGoogle Scholar
  12. 12.
    R. A. Chalmers, R. Parker, H. A. Simmonds, W. Sneddon, and R. W. E. Watts, The conversion of 4-hydroxypyrazolo[3, 4-d]pyrimidine (allopurinol) into 4, 6-dihydroxypyrazolo[3, 4-d]pyrimidine (oxypurinol) in vivo in the absence of xanthine-oxygen oxidore reductase, Biochem. J. 112: 527 (1969)PubMedGoogle Scholar
  13. 13.
    C. Auscher, C. Pasquir, N. Mercier, and F. Delbarre, Oxidation of pyrazolo[3, 4-d]pyrimidine in a xanthinuric man, Isr. J. Med. Sd. 8: 1082 (1974)Google Scholar
  14. 14.
    H. Yamanaka, K. Nishioka, T. Suzuki, and K. Kohno, Allopurinol metabolism in a patient with xanthine oxidase deficiency, Ann. Rheum. Dis. 42: 684 (1983)PubMedCrossRefGoogle Scholar
  15. 15.
    T. Yamamoto, Y. Moriwaki, S. Takahashi, T. Hada, and K. Higashino, Separation of hypoxanthine and xanthine from pyrazinamide and its metabolites in plasma and urine by high-performance liquid chromato-graphy, J. Chromatogr. 382: 270 (1986)PubMedCrossRefGoogle Scholar
  16. 16.
    V. E. Shih, M. M. Carney, and R. Mandell, A simple screening test for sulfite oxidase deficiency: detection of urinary thiosulfate by modification of Sorbo’s method, Clin. Chim. Acta 95: 143 (1979)PubMedCrossRefGoogle Scholar
  17. 17.
    J. Johnson, W. Wand, K. V. Rajagopalan, M. Duran, F. A. Beemer, and S. V. Wadman, Inborn errors of molybdenum metabolism: combined deficiences of sulfite oxidase and xanthine dehydrogenase in a patient laking the molybdenum cofactor, Proc. Natl. Acad. Sci. USA 77: 3715 (1980)PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • Kazuya Higashino
    • 1
  • Tetsuya Yamamoto
    • 1
  • Toshikazu Hada
    • 1
  • Norio Kono
    • 2
  • Masanori Kawachi
    • 2
  • Masahisa Nanahoshi
    • 3
  • Sumio Takahashi
    • 1
  • Michio Suda
    • 1
  • Michiko Naka
    • 1
  1. 1.The Third Department of Internal MedicineHyogo College of MedicineNishinomiya, Hyogo 663Japan
  2. 2.The Second Department of Internal MedicineOsaka University Medical SchoolFukushima, Osaka 553Japan
  3. 3.The Department of Internal MedicineKinki-Central-Hospital of The Mutual Aid Association of Public School TeachersItami, Hyogo 664Japan

Personalised recommendations